Yüksel Ürün· @DrYukselUrun · X·· 2 天前评分90
正文 · 机器翻译
ctDNA 是一种风险信号，但目前还无法指引治疗决策？
KEYNOTE-B15：EV/pembro 与化疗的清除率分别为 82.1% 和 66.7%。我们何时才能安全地据此采取行动？
@myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @tompowles1 @urologysummit @isliquidbiopsy
487 浏览 · 7 赞 · 7 转发 · 0 回复
会议摘要
4734O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.orgNCT04700124NCT04700124按 - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) 对上
- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.org来源：Yüksel Ürün · x.com